gMendel’s Post

📢 [MEMBER'S EVENT - HEALTHCARE] 🧬 Our members Horiana and Okomera invite you to a scientific event on MultiOmics data integration across scales: From Cells to Populations. 📅 Thursday, May 23rd ⏰ From 6PM PST 📌 MindsDB, 3154 17th St, San Francisco 👉 Register here: https://lu.ma/3dsyfmty This event aims at showcasing key innovative methods and success in the integration of high-resolution (multi-omics) data. Taking real-world examples from systems biology and population health sciences we will illustrate which and how statistical, AI/MLapproaches can be used for interpretable and useful data integration. We will highlight commonalities, specificities and complementarities of the approaches to clarify the need for improved interoperability across these fields for accelerated impact.   The speakers will deliver concise presentations of their research and they will participate to an interactive Q&A session with the moderator and the audience.   Introduction by Hocine Lourdani, PharmD: Founder & CEO, Entity Bio   Antoine Forget, PhD. Associate Professional Researcher in Cellular and Molecular Pharmacology, QBI, University of California, San Francisco, California, USA Title: "Unlocking Cancer Complexity: Integrating Multiomic Molecular Data for Interpretable Machine Learning and Systems Biology Insights"   Marc Chadeau-Hyam, PhD : Professor of Computational Epidemiology and Biostatistics, Imperial College London, UK. Title: Data Integration in Exposome Research: definition, needs and Examples. #members #faccsf #science #health #biotech #biology #data

🦓 As the Europe Rare Disease Summit progresses, we're thrilled to kick off one of our most anticipated panels: 'The Role of Technology in Rare Disease-Specific Registry and Diagnostic'. In an era where technology and healthcare intersect more than ever, this panel promises to shed light on groundbreaking advancements. We'll explore how innovative technologies are revolutionizing rare disease registries and diagnostics, paving the way for more personalized and effective treatments. Introducing our esteemed panelists: 👉  Francesc Martínez Palau, Scientific Coordinator of the Strategy for Rare Diseases, National Health System (Spain) 👉 Miguel Segura, Neural Tumor Laboratory; Translational Research in Childhood and Adolescent Tumors, , Hospital Universitario Vall D'Hebrón (Spain) 👉 Nuno Miguel Piedade Silverio, Grupo de Trabalho das Doenças Raras, Associação Portuguesa de Bioindústria (P-BIO) (Portugal) 👉 Marisol Montolio, Director of Research Department and Technology Department Duchenne Parent Project Spain. Scientific Director of Cátedra Enfermedades Raras Universidad de Barcelona. ePAG ERN neuromuscular, Universidad de Barcelona (Spain) 👉 Peter Fish, Digital Health and Clinical Innovation, CEO, Mendelian (United Kingdom) Chiesi Global Rare Diseases | Horizon | Grifols | Blueprint Genetics | CENTOGENE| Mendelian | Fundación Bamberg #bamberghealth #EURDS #RDSseries #raredisease #rds #enfermedadesraras

I'm excited to share some of the most significant results from my doctoral research, presented in the article titled "Synthesis and activity of benzimidazole N-Acylhydrazones against Trypanosoma cruzi, Leishmania amazonensis and Leishmania infantum". In this study, we focused on the design, synthesis, and cytotoxic evaluation of a series of benzimidazole N-acylhydrazones against strains of Trypanosoma cruzi (Y and Tulahuen) and species of Leishmania (L. amazonensis and L. infantum). The highlight of our research was the compound (E)-N'-((5-Nitrofuran-2-yl)methylene)-1H-benzo[d]imidazole-2-carbohydrazide, which demonstrated significant activity against both trypomastigote and amastigote forms (Tulahuen strain), with an IC50/120 h of 0.033 μM and a selectivity index (SI) of 7680. This compound exhibited 46 times greater potency than benznidazole (IC50/120 h = 1.520 μM, SI = 1390). Another promising compound was (E)-N'-(2-Hydroxybenzylidene)-1H-benzo[d]imidazole-2-carbohydrazide, which showed significant activity against trypomastigote and amastigote forms (Tulahuen strain), with an IC50/120 h of 3.600 μM and an SI of 14.70. However, its efficacy against L. infantum and L. amazonensis was comparatively lower. These findings provide valuable insights for the development of more effective treatments against Trypanosoma cruzi, contributing to the fight against neglected diseases such as Chagas disease and Leishmaniasis. I'm grateful to all my colleagues and mentors who supported me throughout this scientific journey. I am eager to continue exploring new frontiers in combating these diseases and collaborating with other researchers dedicated to improving global health. #chagasdisease #Leishmaniasis #neglecteddiseases Read the full articule at the link. https://lnkd.in/dV-rBQH7.

🌐 Unlocking New Frontiers in Research: BiomLife® by Ruhvenile (www.ruhvenile.com) Paving the Way for Breakthroughs in Liver Diseases, Microbiome Analysis and omics studies… I'm thrilled to share the transformative impact of BiomLife®, our cutting-edge specimen preservation solution, on advancing research in liver diseases and microbiome analysis. BiomLife® is not just a product; it's a gateway to precision and innovation across diverse industries. BiomlIfe (>50000) is tested in four continents for advance studies including liver diseases... 🔍 Perfect Market Fit: Versatile across healthcare, agriculture, and environmental research, BiomLife® stands as a universal solution addressing diverse needs with unparalleled precision. Offering a formalin-free alternative, it aligns seamlessly with market preferences for safety and environmental consciousness. 🌱 Standout Features: BiomLife® goes beyond expectations. It maintains specimen viability for over two years, meeting the demand for prolonged studies and in-depth analyses. As a universal formalin and protein-free transport medium, it caters to liquid, solid, and tissue specimens, preserving DNA, RNA, and a myriad of microbes without proliferation. 💡 Advancing Research Horizons: From PCR and RT-PCR to sequencing, metagenomics, metabolomics, proteomics, and functional genomics, BiomLife® empowers advanced molecular studies. It is complementing groundbreaking research on four continents, notably contributing to liver diseases analysis, personalized medication, and public health initiatives. 🌍 Globally Recognized and Validated: BiomLife® enjoys credibility among institutions and researchers worldwide, positioning itself as a trusted choice in the realm of specimen preservation. Its strategic role in disease control aligns with the market's emphasis on health security. 🤝 Join the BiomLife® Revolution: As BiomLife® continues to catalyze success in current applications, we actively seek collaborations and partnerships. If you are in search of a transformative solution tailored to today's market dynamics, BiomLife® is your answer. Let's redefine possibilities in research together. Connect with us, and let BiomLife® be the catalyst for your next scientific breakthrough. info@ruhvenile.com, 0091 858 7033367, 0091 11 3501 7209 #BIRAC #liverhealth #liverdisease #gastroenterology #cancerresearch #personalisedmedicine #hospitals #microbiomeresearch

🌐 Unlocking New Frontiers in Research: BiomLife® by Ruhvenile (www.ruhvenile.com) Paving the Way for Breakthroughs in Liver Diseases, Microbiome Analysis and omics studies… I'm thrilled to share the transformative impact of BiomLife®, our cutting-edge specimen preservation solution, on advancing research in liver diseases and microbiome analysis. BiomLife® is not just a product; it's a gateway to precision and innovation across diverse industries. BiomlIfe (>50000) is tested in four continents for advance studies including liver diseases... 🔍 Perfect Market Fit: Versatile across healthcare, agriculture, and environmental research, BiomLife® stands as a universal solution addressing diverse needs with unparalleled precision. Offering a formalin-free alternative, it aligns seamlessly with market preferences for safety and environmental consciousness. 🌱 Standout Features: BiomLife® goes beyond expectations. It maintains specimen viability for over two years, meeting the demand for prolonged studies and in-depth analyses. As a universal formalin and protein-free transport medium, it caters to liquid, solid, and tissue specimens, preserving DNA, RNA, and a myriad of microbes without proliferation. 💡 Advancing Research Horizons: From PCR and RT-PCR to sequencing, metagenomics, metabolomics, proteomics, and functional genomics, BiomLife® empowers advanced molecular studies. It is complementing groundbreaking research on four continents, notably contributing to liver diseases analysis, personalized medication, and public health initiatives. 🌍 Globally Recognized and Validated: BiomLife® enjoys credibility among institutions and researchers worldwide, positioning itself as a trusted choice in the realm of specimen preservation. Its strategic role in disease control aligns with the market's emphasis on health security. 🤝 Join the BiomLife® Revolution: As BiomLife® continues to catalyze success in current applications, we actively seek collaborations and partnerships. If you are in search of a transformative solution tailored to today's market dynamics, BiomLife® is your answer. Let's redefine possibilities in research together. Connect with us, and let BiomLife® be the catalyst for your next scientific breakthrough. info@ruhvenile.com, 0091 858 7033367, 0091 11 3501 7209 #BIRAC #liverhealth #liverdisease #gastroenterology #cancerresearch #personalisedmedicine #hospitals #microbiomeresearch

Prior research has long established the existence of microbiomes in the gut and skin, but could there also be a structured microbial community in our bloodstream? 🤔 Seeking concrete proof, researchers at the Genome Institute of Singapore (GIS) and Nanyang Technological University Singapore conducted a comprehensive analysis of sequencing data from Phase I of the National Precision Medicine Strategy—examining microbial signatures from nearly 10,000 participants. 🔍 The team detected 117 microbial species which mainly originated from the gut, mouth and genitourinary microbiomes, contrary to claims regarding a native blood microbiome in healthy individuals. However, A*STAR scholar Cedric Tan notes that further investigation is still necessary: “Our findings do not exclude the possibility that there might be a more persistent community of blood microbes in patients with chronic diseases such as cancer, cardiovascular disease or diabetes.” Follow the link in the comments section to view the complete article ⬇️ --- #scicomm #science #technology #STEM #research #innovation #ASTAR #GIS #HHP #microbiome #sequencing #microbiology

🌟 Reflecting on the Last Day of 2023 🌟 As we bid adieu to 2023, I'm thrilled to share a special moment from the year's end—a day immersed in insightful discussions with Key Opinion Leaders (KOLs) in the field of genetics, specifically focusing on the groundbreaking advancements discussed at the First Hybrid Symposium on NGS in the Diagnosis and Treatment of Diseases and Personalized Medicine in Iran. 🧬 The discussions were nothing short of illuminating, delving into the forefront of genetic research, innovative technologies, and the promising future of personalized medicine. It's truly inspiring to witness the dedication and expertise of these thought leaders who are shaping the landscape discussed at the symposium. 🌐 Amidst these conversations, the symposium highlighted the enduring power of Sanger sequencing in diagnostics. The convergence of Next-Generation Sequencing (NGS) and the time-tested Sanger sequencing method was a focal point, underscoring the importance of integrating innovative approaches like NGS with the robustness of Sanger sequencing for comprehensive insights into genomic information. 💡 Delving deeper, the dialogue emphasized the unique strengths of Sanger sequencing, showcasing its role in providing accurate and detailed genetic information. The symposium became a platform for exploring how this integration could further enhance diagnostic methodologies. 🚀 The day was a testament to the power of collaboration and the shared vision of advancing genetic knowledge. Grateful for the opportunity to engage in meaningful conversations and contribute to the ongoing dialogue on the transformative role of NGS and Sanger sequencing in healthcare. Looking forward to more collaborative breakthroughs and shared discoveries in the coming year! 🌐🧬💡🚀 #NGS #SangerSequencing #GeneticAdvancements #Collaboration #2023Reflections #NewYearNewPossibilities #nextgenerationsequencing #wholegenomesequencing

🔬 Exciting News for Scientists!🔬 Introducing: Nature Springer’s Borrelia burgdorferi: Methods and Protocols. Methods in Molecular Biology. Editor Leona Gilbert. https://lnkd.in/dyW8d6V6 📚 From cell and molecular biologists to statisticians and clinical researchers, these methods cater to all fields. Explore techniques for in vitro, in vivo, in situ, de novo, and clinical studies of Borrelia burgdorferi. Let's advance our understanding of infectious diseases! 💪🌍 Chapter 8 Revealed. 🧬 Revolutionizing Lyme Disease Diagnosis: The Power of Borrelia Phages 🧬 Researchers Jinyu Shan, Ying Jia, and Tatjana Mijatovic are pioneering the fight against tick-borne infections with a new potential diagnostic approach: Borrelia-specific phages. 🔍 Using the accuracy of real-time PCR, the method targets circulating bacteriophage DNA, allowing a direct detection of Borrelia that is much better than traditional PCR tests. 💡 Why phages? These viruses, which are intimately linked to their bacterial hosts, are usually more abundant in the blood, thus enabling a higher rate of detection. Plus, they can distinguish between different Lyme and Relapsing Fever-causing Borrelia strains, ensuring accurate diagnosis from early to late stages. Stay tuned for more updates as we bring this innovative technology to the forefront of healthcare! #LymeDisease #DiagnosticBreakthrough #BorreliaPhages #InnovativeResearch #LeicesterUniversity #TickborneDisease

Today marks an important milestone with Kansai Medical University and Genesis Healthcare announcing a collaborative research initiative that harnesses genomic big data and A.I. in Japan. We are thrilled to unveil the nation's first joint research project, merging the genomic big data from both organizations and utilizing artificial intelligence to drive breakthroughs in psychiatric, immune, cardiovascular, and respiratory diseases. Read more at https://lnkd.in/gVC3R7Aa #KMU #kansaimedicaluniveristy #genesishealthcare #genelife #genesisgaia #genesispro #genetics #biotech #techbio #genomics #genomicdata #Japan #asia #lifesciences #JapanBio #research #R&D #wgs #sequencing #bigdata #AI #genomicdata

🔬 Exciting News for Scientists!🔬 Introducing: Nature Springer’s Borrelia burgdorferi: Methods and Protocols. Methods in Molecular Biology. Editor Leona Gilbert. https://lnkd.in/dyW8d6V6 📚 From cell and molecular biologists to statisticians and clinical researchers, these methods cater to all fields. Explore techniques for in vitro, in vivo, in situ, de novo, and clinical studies of Borrelia burgdorferi. Let's advance our understanding of infectious diseases! 💪🌍 Chapter 8 Revealed. 🧬 Revolutionizing Lyme Disease Diagnosis: The Power of Borrelia Phages 🧬 Researchers Jinyu Shan, Ying Jia, and Tatjana Mijatovic are pioneering the fight against tick-borne infections with a new potential diagnostic approach: Borrelia-specific phages. 🔍 Using the accuracy of real-time PCR, the method targets circulating bacteriophage DNA, allowing a direct detection of Borrelia that is much better than traditional PCR tests. 💡 Why phages? These viruses, which are intimately linked to their bacterial hosts, are usually more abundant in the blood, thus enabling a higher rate of detection. Plus, they can distinguish between different Lyme and Relapsing Fever-causing Borrelia strains, ensuring accurate diagnosis from early to late stages. Stay tuned for more updates as we bring this innovative technology to the forefront of healthcare! #LymeDisease #DiagnosticBreakthrough #BorreliaPhages #InnovativeResearch #LeicesterUniversity #TickborneDisease